CJEMHumansAtrial FibrillationCost-Benefit AnalysisAnticoagulantsElectric Countershock
Cost-utility analysis of routine oral anticoagulation for low-risk patients undergoing cardioversion for atrial fibrillation and flutter.
Shawn Chhabra, Krishan Yadav, Miguel Cortel-LeBlanc, Adam Costello, Ian Stiell, Kednapa Thavorn
Published: 202510.1007/s43678-025-00991-6
Abstract
PURPOSE: Canadian guidelines suggest that physicians should consider prescribing four weeks of oral anticoagulation (OAC) for patients undergoing cardioversion for acute atrial fibrillation/flutter (AF/AFL), regardless of stroke risk. While the risk…
Preview only. Read the full abstract at the source